公开(公告)号：US20230405139A1

公开(公告)日：2023-12-21

申请号：US18209299

申请日：2023-06-13

申请人： LegoChem Biosciences, Inc. ,  ABL Bio, Inc.

发明人： Yun-Hee Park ,  Ho Young Song ,  Hyun Min Ryu ,  Sung Min Kim ,  Ju Yuel Baek ,  Ji Hye Oh ,  Nara Han ,  Hyoung Rae Kim ,  Kyung Eun Park ,  Hyeun Joung Lee ,  Ju Young Lee ,  Dae Hyuck Kang ,  Young-Jae Yang ,  Ji-na You ,  Yong Zu Kim ,  Chang Sun Lee ,  Jeiwook Chae ,  Jinwon Jung ,  Juhee Kim ,  Bora Lee ,  Daehae Song ,  Byungje Sung ,  Donghoon Yeom ,  Jaehyun Eom ,  Youngeun Hong ,  Jinhyung Ahn ,  Yangsoon Lee ,  Kyungjin Park ,  Jiseon Yoo ,  Minji Park

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K47/6849 ,  A61P35/00 ,  A61K47/6803 ,  C07K16/2803

摘要： The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

公开(公告)号：US11707533B2

公开(公告)日：2023-07-25

申请号：US16940326

申请日：2020-07-27

申请人： LegoChem Biosciences, Inc. ,  ABL Bio, Inc.

发明人： Yun-Hee Park ,  Ho Young Song ,  Hyun Min Ryu ,  Sung Min Kim ,  Ju Yuel Baek ,  Ji Hye Oh ,  Nara Han ,  Hyoung Rae Kim ,  Kyung Eun Park ,  Hyeun Joung Lee ,  Ju Young Lee ,  Dae Hyuck Kang ,  Young-Jae Yang ,  Ji-Na You ,  Yong Zu Kim ,  Chang Sun Lee ,  Jeiwook Chae ,  Jinwon Jung ,  Juhee Kim ,  Bora Lee ,  Daehae Song ,  Byungje Sung ,  Donghoon Yeom ,  Jaehyun Eom ,  Youngeun Hong ,  Jinhyung Ahn ,  Yangsoon Lee ,  Kyungjin Park ,  Jiseon Yoo ,  Minji Park

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K47/6849 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/2803

摘要： The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

公开(公告)号：US12049493B2

公开(公告)日：2024-07-30

申请号：US16475853

申请日：2018-01-05

申请人： ABL Bio Inc.

发明人： Jinhyung Ahn ,  Sungwon An ,  Dongin Kim ,  Eunsil Sung ,  Jaehyun Eom ,  Sang Hoon Lee ,  Seung-Jae Lee ,  Tae Kyung Kim ,  Min Sun Choi ,  Weonkyoo You ,  Jaeho Jung ,  Juhee Kim ,  Jinwon Jung ,  Yeunju Kim ,  Yonggyu Son ,  Byungje Sung

IPC分类号： C07K16/18 ,  A61K39/00 ,  A61P25/14 ,  G01N33/68

CPC分类号： C07K16/18 ,  A61P25/14 ,  G01N33/6896 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  G01N2800/2835

摘要： The disclosure discloses anti α-Syn antibodies preferentially recognizing α-Syn aggregates. The antibodies of the present invention bind to α-Syn aggregates with high affinity and specificity and inhibit accumulation or intercellular transfer of α-Syn aggregates, and thus can be used for detection, diagnosis and/or treatment or prevention of various diseases caused by the accumulation of α-Syn aggregates.

公开(公告)号：US12071483B1

公开(公告)日：2024-08-27

申请号：US16770728

申请日：2018-12-14

申请人： ABL Bio Inc.

发明人： Jinhyung Ahn ,  Sungwon An ,  Dongin Kim ,  Eunsil Sung ,  Jaehyun Eom ,  Sang Hoon Lee ,  Weonkyoo You ,  Juhee Kim ,  Kyungjin Park ,  Hyejin Chung ,  Jinwon Jung ,  Bora Lee ,  Byungje Sung ,  Yeunju Kim ,  Yong-Gyu Son ,  Seawon Ahn ,  Daehae Song ,  Jiseon Yoo ,  Youngdon Pak ,  Donghoon Yeom ,  Yoseob Lee ,  Jaeho Jung

IPC分类号： A61K39/395 ,  A61K47/68 ,  C07K16/18 ,  C07K16/28

CPC分类号： C07K16/2863 ,  A61K47/6845 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/567

摘要： The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

公开(公告)号：US20230212217A1

公开(公告)日：2023-07-06

申请号：US17789163

申请日：2020-12-24

申请人： ABL BIO INC.

发明人： Daehae Song ,  Youngdon Pak ,  Jinwon Jung ,  Junghyeon Hong ,  Heejin Lim ,  Dongin Kim

IPC分类号： C07K1/22

CPC分类号： C07K1/22

摘要： Provided is a method of purifying a mixture of Fc-containing bioactive peptides by using an affinity column including an affinity matrix containing a protein A ligand, wherein the mixture of Fc-containing bioactive peptides includes a first Fc-containing bioactive peptide and a second Fc-containing bioactive peptide, and the second Fc-containing bioactive peptide includes at least one more human VH3 domain, compared to the first Fc-containing bioactive peptide. According to the purification method, bioactive peptides having the same or similar structures can be precisely separated to the high level of purity while simplification of the process is achieved.